Summary of Novo Nordisk Conference Call Company and Industry - **Company**: Novo Nordisk - **Industry**: Pharmaceutical, specifically focusing on obesity treatments and GLP-1 receptor agonists Key Points and Arguments REDEFINE 4 Trial Results - The REDEFINE 4 trial was an open-label study comparing the efficacy and safety of **CagriSema 2.4 mg** to **Tirzepatide 15 mg** in approximately **800** participants with obesity and comorbidities [4][5] - CagriSema achieved a **23%** reduction in body weight after **84 weeks**, while Tirzepatide resulted in a **25.5%** weight loss, failing to meet the primary endpoint of non-inferiority [5][6] - The trial was extended to **84 weeks** based on learnings from REDEFINE 1, but not all optimizations were implemented [4][6] Safety and Tolerability - The safety profile of CagriSema was consistent with previous trials, with gastrointestinal issues being the most common adverse events, generally mild to moderate [6] - The open-label design may have introduced bias favoring Tirzepatide, as many investigators were familiar with it, potentially affecting dosing adherence [6][27] Future Trials and Developments - CagriSema was submitted to the **FDA** for obesity treatment in **December 2025**, with a decision expected later this year [7] - The REDEFINE 11 trial is anticipated to explore the full weight loss potential of CagriSema, with results expected in the first half of **2027** [7][8] - Plans to initiate a Phase 3 trial for a high-dose CagriSema in the second half of **2026** were mentioned [8] Product Differentiation and Market Strategy - CagriSema aims to build upon the **Wegovy** brand, offering multiple treatment options for weight loss, including the recently launched **Wegovy pill**, which has shown a weight loss of close to **17%** [9][10] - The high-dose Wegovy is approved in the EU and UK, with a US decision expected by the end of Q1 [10] - Novo Nordisk is also advancing next-generation obesity treatments, including **zenagamtide**, which showed up to **24%** weight loss in Phase 2 trials [10][11] Competitive Landscape - The company believes CagriSema has the best weight loss efficacy compared to current market offerings, despite the recent trial results [36] - Concerns were raised about CagriSema's competitiveness against high-dose semaglutide and Tirzepatide, but the company maintains confidence in its product's unique benefits [57][59] Research and Development Insights - The company is leveraging insights from the REDEFINE program to enhance future trials, including the **AMAZE** program for zenagamtide [11][59] - There are ongoing discussions about the potential for additional head-to-head studies based on the outcomes of REDEFINE 11 [44][75] Other Important Content - The call included a Q&A session where analysts inquired about trial methodologies, dosing discrepancies, and the implications of the trial results on future product positioning [12][14][21][48] - The open-label nature of the REDEFINE 4 trial was highlighted as a significant factor that could have influenced the results, emphasizing the need for blinded studies in future comparisons [27][75]

Core Viewpoint - Recently, Innovent Biologics announced that its high-dose 9mg injection of Ma Shidu Peptide has received acceptance for listing application from the National Medical Products Administration of China, aimed at long-term weight control for adults with moderate to severe obesity [1] Group 1: Clinical Research Results - The Phase III clinical study GLORY-2 demonstrated outstanding results for Ma Shidu Peptide in the Chinese population with moderate to severe obesity, showing an average weight reduction of 18.55% in the 9mg group at week 60, compared to only 3.02% in the placebo group [1] - In the 9mg group, 44.0% of participants achieved a weight reduction of 20% or more, while only 2.6% in the placebo group reached this threshold (P values less than 0.0001) [1] Group 2: Additional Health Benefits - The study also indicated a significant average percentage reduction of 71.9% in liver fat content for the 9mg group, along with notable improvements in key cardiovascular metabolic indicators such as blood pressure, blood lipids, and uric acid levels [1] - The safety profile of the drug was reported to be good, with no new safety signals identified [1]

Core Viewpoint - Gilead Sciences-B (01672) saw a significant increase of over 7%, currently trading at 10.11 HKD, with a transaction volume of 21.57 million HKD, following its inclusion in the MSCI Global Small Cap Index, effective after the market close on November 24 [1] Group 1: MSCI Inclusion - Gilead Sciences-B has been included in the MSCI Global Small Cap Index as announced by MSCI on November 6 [1] - The adjustment from MSCI will take effect after the market closes on November 24 [1] Group 2: Clinical Research Updates - Gilead Sciences-B presented multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, including a complete analysis of the ASC30 oral tablet Phase Ib study [1] - The ASC30 oral tablet study showed an average weight loss of up to 6.5% after placebo adjustment, demonstrating good safety and tolerability with only mild to moderate gastrointestinal adverse events [1] - The apparent half-lives of the ASC30 injection were 46 days and 75 days, supporting monthly and quarterly dosing regimens [1]

Financial Data and Key Metrics Changes - Research and development expenses for Q3 2025 were $90 million, up from $22.8 million in Q3 2024, primarily due to increased clinical study expenses and salaries [6] - General and administrative expenses decreased to $8.6 million in Q3 2025 from $13.8 million in Q3 2024, mainly due to reduced legal and patent service costs [6] - The net loss for Q3 2025 was $90.8 million or $0.81 per share, compared to a net loss of $24.9 million or $0.22 per share in Q3 2024 [7][8] - For the first nine months of 2025, research and development expenses totaled $191.5 million, up from $70.7 million in the same period in 2024 [8] - The net loss for the first nine months of 2025 was $202 million or $1.80 per share, compared to a net loss of $74.5 million or $0.69 per share in the same period in 2024 [9] Business Line Data and Key Metrics Changes - The company announced positive top-line results from the phase two clinical trial of VK2735, achieving significant weight loss in patients with obesity [4][26] - VK2735 demonstrated statistically significant reductions in body weight, with up to 14.7% weight loss after 13 weeks in the Venture Oral Dosing Study [11][17] - The study also indicated that VK2735 was safe and well-tolerated, with most adverse events being mild or moderate [5][20] Market Data and Key Metrics Changes - The Vanquish Registration Program is currently enrolling approximately 4,500 patients for the obesity trial and 1,100 patients for the obesity and type 2 diabetes trial [13][14] - Enrollment for the Vanquish studies is proceeding well, with expectations to complete enrollment by the end of 2025 for Vanquish One and in Q1 2026 for Vanquish Two [14][25] Company Strategy and Development Direction - The company is advancing both subcutaneous and oral formulations of VK2735 for obesity treatment, aiming to provide options for patients [10][15] - A phase one study has been initiated to evaluate maintenance dosing regimens following initial weight loss achieved with VK2735 [23] - The company is also progressing with novel agonists targeting the amyloid receptor, with an IND filing expected in Q1 2026 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the enrollment pace in the Vanquish studies, indicating enthusiasm for the program [29] - The company plans to submit an end-of-phase two meeting request to the FDA to discuss potential next steps for the oral formulation of VK2735 [26] - Management noted that the financial position is strong, with $715 million in cash available to support ongoing and future development programs [25] Other Important Information - The company is preparing for potential commercialization strategies, remaining open to partnerships while also being ready to proceed independently [82] - The results from the Venture Oral Dosing Study are expected to be published in a leading medical journal in early 2026 [12] Q&A Session Summary Question: Early signs of patient persistence and trial execution - Management noted that enrollment is ahead of schedule and there are no signs of persistence issues at this early stage [29] Question: Details on the maintenance study induction phase - The induction phase will involve titration up to doses of 17.5 mg, 20 mg, and 22.5 mg over 19 weeks [30] Question: Doses for monthly sub-Q, daily oral, and weekly oral being tested - Monthly doses will range from 15 mg to 22.5 mg, with daily doses at 17.5 mg and 27.5 mg, and weekly oral at 110 mg [34] Question: Next steps for validating a maintenance regimen - Management indicated that a longer study may be needed depending on the data from the maintenance study [38] Question: Impact of government shutdown on enrollment and timing - Management reported no significant impact from the government shutdown on enrollment or communication with the FDA [40] Question: Considerations for leveraging maintenance data with payers - Management emphasized the importance of persistence in therapy and ongoing discussions with payers regarding maintenance options [48] Question: Future plans for VK2809 in the MASH space - Management acknowledged increased interest in the MASH space and noted ongoing discussions regarding VK2809 [66]